Compare VIRT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIRT | ABCL |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | 2014 | 2020 |
| Metric | VIRT | ABCL |
|---|---|---|
| Price | $53.28 | $12.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $69.43 | $16.82 |
| AVG Volume (30 Days) | 1.1M | ★ 4.3M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 72.73 | 10.91 |
| EPS | ★ 3.62 | N/A |
| Revenue | ★ $3,632,118,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.12 |
| P/E Ratio | $15.00 | ★ N/A |
| Revenue Growth | 26.25 | ★ 160.56 |
| 52 Week Low | $31.55 | $2.75 |
| 52 Week High | $68.76 | $14.98 |
| Indicator | VIRT | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 48.43 |
| Support Level | $51.56 | $11.78 |
| Resistance Level | $56.48 | $12.88 |
| Average True Range (ATR) | 1.92 | 0.83 |
| MACD | -0.23 | 0.01 |
| Stochastic Oscillator | 17.59 | 40.11 |
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.